ARON-1: IO Versus TKI for Papillary Renal Cell Carcinoma | GU Oncology Now
The ARON-1 study investigated the efficacy of first-line treatment with TKIs versus IO-based combinations in patients with pRCC, the most common histological subtype of nccRCC.